Axonics, Inc. AXNX
We take great care to ensure that the data presented and summarized in this overview for Axonics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AXNX
View all-
Vanguard Group Inc Valley Forge, PA5.04MShares$354 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.34MShares$305 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ2.11MShares$148 Million6.8% of portfolio
-
Fil LTD Hamilton, D02.04MShares$143 Million0.14% of portfolio
-
George Soros Soros Fund Management LLC | New York, Ny1.77MShares$125 Million2.93% of portfolio
-
Westchester Capital Management, LLC Valhalla, NY1.35MShares$95 Million3.73% of portfolio
-
Norges Bank Oslo, Q81.27MShares$89.3 Million0.01% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A61.26MShares$88.5 Million0.13% of portfolio
-
Omni Event Management LTD London, X01.22MShares$85.7 Million9.41% of portfolio
-
State Street Corp Boston, MA1.21MShares$85.1 Million0.0% of portfolio
Latest Institutional Activity in AXNX
Top Purchases
Top Sells
About AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Insider Transactions at AXNX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 02
2024
|
Kari Leigh Keese Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,961
-3.44%
|
$204,309
$69.41 P/Share
|
|
Jul 24
2024
|
Raymond W Cohen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
103,896
+15.89%
|
$2,077,920
$20.01 P/Share
|
|
Jan 31
2024
|
Karen Noblett Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,288
-24.69%
|
$756,296
$67.74 P/Share
|
|
Jan 31
2024
|
Karen Noblett Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+37.56%
|
-
|
|
Jan 31
2024
|
Rinda Sama Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+25.03%
|
-
|
|
Jan 31
2024
|
Raymond W Cohen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
35,161
-15.7%
|
$2,355,787
$67.74 P/Share
|
|
Jan 31
2024
|
Raymond W Cohen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,400
+22.06%
|
-
|
|
Jan 31
2024
|
Kari Leigh Keese Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,489
-7.45%
|
$233,763
$67.74 P/Share
|
|
Jan 31
2024
|
Kari Leigh Keese Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,167
+11.64%
|
-
|
|
Jan 31
2024
|
Alfred J Ford Jr Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
16,615
-27.66%
|
$1,113,205
$67.74 P/Share
|
|
Jan 31
2024
|
Alfred J Ford Jr Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,500
+29.8%
|
-
|
|
Jan 31
2024
|
John Woock EVP, Chief Mktg/Strtgy Officer |
SELL
Open market or private sale
|
Direct |
15,899
-17.04%
|
$1,065,233
$67.74 P/Share
|
|
Jan 31
2024
|
John Woock EVP, Chief Mktg/Strtgy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+23.08%
|
-
|
|
Jan 08
2024
|
Karen Noblett Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,999
-46.76%
|
$1,103,931
$69.0 P/Share
|
|
Dec 28
2023
|
Karen Noblett Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,051
-17.09%
|
$444,213
$63.28 P/Share
|
|
Dec 26
2023
|
Karen Noblett Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
949
-2.25%
|
$59,787
$63.0 P/Share
|
|
Sep 29
2023
|
Danny L. Dearen President & CFO |
SELL
Open market or private sale
|
Direct |
7,675
-24.4%
|
$429,800
$56.87 P/Share
|
|
Sep 29
2023
|
Danny L. Dearen President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+26.35%
|
-
|
|
Aug 15
2023
|
Alfred J Ford Jr Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
14,769
-29.94%
|
$915,678
$62.34 P/Share
|
|
Aug 08
2023
|
Michael H Carrel |
SELL
Bona fide gift
|
Direct |
500
-2.72%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 282K shares |
|---|
| Open market or private sale | 109K shares |
|---|